Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genethon

Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV
From Genethon
Via Business Wire
Genethon Confirms 2-Year Efficacy in Duchenne Muscular Dystrophy Patients Treated With Its Low Dose Micro-Dystrophin Gene Therapy (GNT0004) at the ESGCT 32nd Annual Congress
From Genethon
Via Business Wire
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
From Genethon
Via Business Wire
Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster’s First International Summit, Atamyo Therapeutics’ Progress for LGMDs Highlight Genethon’s Most Recent Newsletter
From Genethon
Via Business Wire
Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025
From Genethon
Via Business Wire
Genethon Celebrates Rare Disease Day by Highlighting New Technologies to Advance Gene Therapies and Bring Hope to Millions of Patients Worldwide
From Genethon
Via Business Wire
A Phase 3 Ready DMD Gene Therapy, a Clinical Trial to Offset AAV Neutralizing Antibodies, and an AI Inspired New Generation of Capsids Highlight Genethon’s 2024 Fall Milestones
From Genethon
Via Business Wire
Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
From Genethon
Via Business Wire
Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago
From Genethon
Via Business Wire
Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31st Annual Congress October 22 – 25, 2024 in Rome, Italy
From Genethon
Via Business Wire
Genethon Announces Publication in Nature Communications of a Next-Generation Gene Therapy Vector for Muscle Diseases, Using AI Predictive Methodology to Improve Efficacy and Safety
From Genethon
Via Business Wire
Marking World Duchenne Muscular Dystrophy Day, Genethon Reaffirms Its Commitment to Helping Patients for 35 Years and Provides an Update on Its Promising Gene Therapy Drug Candidate for This Fatal Disease
From Genethon
Via Business Wire
Positive Results from Genethon’s Gene Therapy Trial for Duchenne Muscular Dystrophy, Advances of Its Spinoff Atamyo in the LGMD and Cardiomyopathy Fields, Highlighted in Latest Newsletter
From Genethon
Via Business Wire
First Clinical Trial Results of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy Presented at International Myology 2024 Congress
From Genethon
Via Business Wire
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases
From Genethon
Via Business Wire
Genethon Using Artificial Intelligence to Improve Effectiveness of Gene Therapies and Patient Access
From Genethon
Via Business Wire
Genethon Announces Publication in The Lancet Neurology of Clinical Trial Results of a Gene Therapy for Myotubular Myopathy, a Severe Muscle Disease
From Genethon
Via Business Wire
Positive Phase 1/2 Clinical Trial Results of Genethon’s Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease, Published in The New England Journal of Medicine
From Genethon
Via Business Wire
GenoTher Biocluster Designation Bolsters French Leadership in Gene Therapy
From Genethon
Via Business Wire
Genethon Given PRIME Status by EMA for Gene Therapy To Treat Crigler-Najjar Syndrome, a Rare Liver Disease
From Genethon
Via Business Wire
Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
From Genethon
Via Business Wire
Gene Therapies Continue to Emerge as Effective Treatments for Rare Diseases, But Complex Challenges Remain
From Genethon
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.